Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 1st Schizophrenia Patch Drug to Hit Japan Market on Sept. 10: Sumitomo Dainippon
September 4, 2019
- Latuda Makes Debut in China: Sumitomo Dainippon
September 4, 2019
- 70% of Japanese ACS Patients Fail to Hit LDL-C Management Goal in Observational Study: Sanofi
September 4, 2019
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
- Higher Rate of Resistance to Xofluza Seen in Younger Children: Shionogi
September 3, 2019
- Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- Kowa Gears Up for Glanatec PII Trial in US
September 3, 2019
- Japan Approves Zykadia’s Smaller Film-Coated Tablets
September 3, 2019
- AstraZeneca, Osaka Govt Join Forces on Anti-Allergy Measures
September 3, 2019
- Digital Technologies Hold Key for Japan’s Participation in Global Studies: IQVIA R&D Solutions Head
September 3, 2019
- Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
- Daiichi Sankyo’s Pain Drug Tarlige Sweeps Promotion Rankings in June: Impact Track
September 2, 2019
- Kadcyla Filed in Japan for Adjuvant Use in Early Breast Cancer
September 2, 2019
- Osaka Startup Looks to Reposition Polaprezinc/Selenium Combination as NASH Treatment
August 30, 2019
- Xofluza Approved in Taiwan: Shionogi
August 30, 2019
- Hisamitsu Seeks Label Expansion for Fentos Tape
August 30, 2019
- 3 Japan Drug Makers Plow US$65 Million into VC Fund
August 30, 2019
- Eisai to Develop Aussie Firm’s Digital Cognitive Function Self-Assessment Tool in Japan
August 29, 2019
- Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…